Total amount: € 0,00
Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus
Cesaro C. 1, Cautiero T. 2, Cautiero V. 2, Cioffi G. 3, Marinelli A. 4, Iezza M. 4, Cesaro F. 5, Turco A. 3, Turco D. 3
1 Ambulatorio di Pneumologia delle Terme di Agnano, Napoli, Italia;
2 Ambulatori di Pneumologia ASL NA1 NA 3 SUD, Napoli, Italia;
3 Unità Operativa Complessa di Broncologia Centralizzata, Azienda Ospedaliera dei Colli di Napoli‑Monaldi, Napoli, Italia;
4 Ambulatorio di ORL delle Terme di Agnano, Napoli, Italia;
5 Unità Operativa Complessa di Medicina Infettivologica e dei Trapianti, Azienda Ospedaliera dei Colli di Napoli‑Monaldi, Napoli, Italia
AIM: Main objective of the study was to evaluate, through the administration of the quality of life cough specific questionnaire (CQLQ), the long-term efficacy of cyclical use of aerosol therapy with hyaluronic acid (HA), N-acetylcysteine (NAC) and chamomile in improving quality of life of patients with chronic cough and chronic obstructive pulmonary disease (COPD) in GOLD stage III-IV. As secondary objective of the study was assessed the impact of the proposed therapeutic protocol in long-term reduction of infectious exacerbations.
METHODS: In this blinded, randomized controlled study, the authors report a two years clinical experience conducted enrolling 98 patients with chronic cough and COPD in GOLD stage III-IV. Forty-nine of 98 enrolled patients were randomly placed in the study group and cyclically subjected to aerosol therapy with AI, NAC, and chamomile, while the remaining 49 patients were assigned to the control group and cyclically subjected to placebo aerosol therapy.
RESULTS: The analysis of the quality of life cough specific questionnaires (CQLQ), administered to 98 patients in the two-year study showed that the therapy group achieved a significant improvement in quality of life compared with placebo group. Also in the 24 month study, using cyclic aerosol therapy with AI, NAC, and chamomile has contributed to determine the reduction of exacerbations compared to placebo-treated group.